VERVE-101 Shows Promise in Treating HeFH, Phase 1b Study Results Show

Heterozygous familial hypercholesterolemia (HeFH) can be difficult to control on available standard-of-care cholesterol-lowering medications. Therapeutic interventions are needed to reduce high LDL cholesterol levels and improve health and quality-of-life for…

Continue Reading VERVE-101 Shows Promise in Treating HeFH, Phase 1b Study Results Show

ACR Convergence 2023: New Data Shared on Dazodalibep for Sjögren’s Syndrome

The American College of Rheumatology (ACR) held its annual scientific meeting -- ACR Convergence 2023 -- from November 10 to 15. During the meeting, stakeholders throughout the field shared insights…

Continue Reading ACR Convergence 2023: New Data Shared on Dazodalibep for Sjögren’s Syndrome

New Partnership will Fund Research for ALK-Positive Non-Small Cell Lung Cancer

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading New Partnership will Fund Research for ALK-Positive Non-Small Cell Lung Cancer
Rare Community Profiles: Battling Renal Cell Carcinoma and Oligodendroglioma Led Tony to Found a Nonprofit for Families Fighting Cancer
Photo courtesy of Tony L.

Rare Community Profiles: Battling Renal Cell Carcinoma and Oligodendroglioma Led Tony to Found a Nonprofit for Families Fighting Cancer

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Battling Renal Cell Carcinoma and Oligodendroglioma Led Tony to Found a Nonprofit for Families Fighting Cancer
Encouraging Findings in Phase 2 Gastric Cancer Clinical Trial
source: pixabay.com

Encouraging Findings in Phase 2 Gastric Cancer Clinical Trial

  Arcus Biosciences and Gilead Sciences issued a press release announcing encouraging overall response rates and six-month progression-free survival rate for their combination treatment of domvanalimab plus zimberelimab and chemotherapy…

Continue Reading Encouraging Findings in Phase 2 Gastric Cancer Clinical Trial
Scientists Demonstrate Gut Microbiome Connection with Transfer of Alzheimer’s to Healthy Animals
source: pixabay.com

Scientists Demonstrate Gut Microbiome Connection with Transfer of Alzheimer’s to Healthy Animals

  Scientists have previously suggested that the gut microbiome plays a role in causing Alzheimer’s disease, and this has now been confirmed. A recent report from ScienceAlert covered a study…

Continue Reading Scientists Demonstrate Gut Microbiome Connection with Transfer of Alzheimer’s to Healthy Animals

ICYMI: Opdivo Now Approved for Patients Aged 12+ with Surgically Resected Stage 2B-C Melanoma

  In the past, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) for different forms of cancer, such as non-small cell lung cancer (NSCLC) and melanoma. More recently,…

Continue Reading ICYMI: Opdivo Now Approved for Patients Aged 12+ with Surgically Resected Stage 2B-C Melanoma
“The Hospital Told Me Not to Come Back Because They Didn’t Know What to do For Me:” An HAE Patient Story
source: pixabay.com

“The Hospital Told Me Not to Come Back Because They Didn’t Know What to do For Me:” An HAE Patient Story

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading “The Hospital Told Me Not to Come Back Because They Didn’t Know What to do For Me:” An HAE Patient Story
Promising Interim Data in Phase 1/2 Hunter Syndrome Trial
source: shutterstock.com

Promising Interim Data in Phase 1/2 Hunter Syndrome Trial

Professionals from all corners of the world convene at SSIEM each year to discuss the latest groundbreaking discoveries. According to a report in BioSpace, one such breakthrough was presented by…

Continue Reading Promising Interim Data in Phase 1/2 Hunter Syndrome Trial